The Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to Anthropic’s board of directors, making him the first pharmaceutical industry executive to join the AI lab’s governing body and giving Trust-appointed directors a majority on the board for the first time.
Summary
- Narasimhan was appointed on April 14 by the Anthropic Long-Term Benefit Trust, a body that represents its non-equity members in Anthropic and exists to elect board directors who are aligned with the company’s mission of social benefit.
- With his appointment, the Trust’s elected directors now have a majority of seats on the seven-person board, a governance limit written into Anthropic’s founding documents but which has not yet been passed.
- The appointment comes as Anthropic weighs in with an IPO at a reported valuation of $380 billion and deepens its push into healthcare through Claude for Life Sciences and Claude for Healthcare.
The Anthropic Trust has appointed Vas Narasimhan, CEO of Novartis, to the board of directors of Anthropic on April 14, 2026. With his arrival, the directors selected by the Long-Term Benefit Trust now hold a majority of the board of seven people, exceeding the management limit of the structure written in the charter of Anthropic which has not been established before.
Narasimhan is a physician and scientist who has overseen the development and regulatory approval of more than 35 new drugs and vaccines at Novartis, one of the world’s largest new pharmaceutical companies. He joined Dario Amodei, Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, and Chris Liddell.
The Anthropic Long-Term Benefit Trust is a separate legal entity that holds a special class of Anthropic stock whose sole purpose is to elect board directors. Its three trustees have no equity in Anthropic, receive no salary from it, and are elected by themselves rather than by shareholders. Current trustees are Buddy Shah of the Clinton Health Access Initiative, Richard Fontaine of the Center for New American Security, and Mariano-Florentino Cuéllar of the Carnegie Endowment for International Peace.
The Trust’s clear mandate is to ensure that Anthropic balances financial success with its social mission of responsibly advancing AI. Trust Chairman Neil “Buddy” Shah said the group was specifically looking for someone who had successfully carried out science with commitment in a highly regulated environment.
Narasimhan is the third director the Trust has placed on the board, joining Trust nominees Jay Kreps and Reed Hastings. Together they now form a majority, a change that gives the Trust’s mandate of safety and public benefit weight in the board’s decision for the first time.
Healthcare Signal
An appointment is not a random appointment. Anthropic launched Claude for Life Sciences in October 2025 and Claude for Healthcare in January 2026, adding HIPAA-ready infrastructure and tools aimed at clinical, regulatory, and scientific workflows. The company has partnerships with Eli Lilly, Novo Nordisk, and Genmab to explore how AI can shorten drug development times.
Bringing a sitting pharma CEO with two decades of experience in the regulated industry gives Anthropic specific expertise on board as Claude deploys at scale in clinical and research areas. Narasimhan said on LinkedIn that “speed alone is not the goal” in healthcare AI, and that “what matters most is how these tools are built, managed, and used in the real world.”
Daniela Amodei said Narasimhan “brings something extraordinary to our board. He has overseen the development and approval of more than 35 novel medicines to benefit patients worldwide in one of the most regulated industries. Getting powerful new technologies to people safely and at scale is what we think about every day at Anthropic.”
The IPO Context
Anthropic’s annual revenue has surpassed $30 billion, up from $9 billion by the end of 2025, as demand for Claude’s models accelerates across businesses. The company is reportedly weighing an IPO of $380 billion, and the board’s composition is increasingly being scrutinized by investors ahead of a public listing.
The addition of a pharmacy CEO to the Trust’s board shows that Anthropic wants its safety-first position to translate into consumer confidence in regulated institutions, not just a PR narrative. For a company preparing to hit the public markets, governance structures are now a matter of course.
